Rapport Therapeutics, Inc. (RAPP) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Rapport Therapeutics, Inc. (NASDAQ:RAPP) is held by 123 institutional firms.

• Institutional ownership in Rapport Therapeutics edged up to 136.0% in September 2025, compared to 105.5% in June 2025.
• Institutional share ownership changed by 29.44% QoQ, while the number of institutional owners saw an increase of 123.64% YoY.
• A review of institutional activity for Rapport Therapeutics shows 86 of 123 filers increasing their positions, while 22 reduced their stake, and 15 remained unchanged.
• The aggregate institutional position in Rapport Therapeutics now stands at 49.63Mn shares as of September 2025, after investors increased their holdings (up by 11.29Mn shares quarter on quarter which is up 21.19Mn shares year over year).
• With 7.14Mn shares, TRV GP V, LLC commands the largest institutional position in Rapport Therapeutics as of September 30, 2025, equating to 19.55% of the company.
• Among the most significant buyers of Rapport Therapeutics during September 2025 were FMR LLC (1.44Mn), GOLDMAN SACHS GROUP INC (1.19Mn), BAKER BROS. ADVISORS LP (997.00K), Vestal Point Capital, LP (950.00K), Polar Capital Holdings Plc (938.95K).
• Leading sellers of Rapport Therapeutics stock in September 2025 included JOHNSON & JOHNSON (713.53K), PRICE T ROWE ASSOCIATES INC /MD/ (423.13K), ALLIANCEBERNSTEIN L.P. (299.07K), CITADEL ADVISORS LLC (144.54K), SECTORAL ASSET MANAGEMENT INC (136.38K).
• The top 10 institutional holders of Rapport Therapeutics for the quarter ending September 2025 included TRV GP V, LLC (7.14Mn), FMR LLC (6.92Mn), ARCH Venture Management, LLC (3.73Mn), Capital International Investors (3.40Mn), Cormorant Asset Management, LP (3.19Mn), GOLDMAN SACHS GROUP INC (2.42Mn), Sofinnova Investments, Inc. (1.95Mn), JOHNSON & JOHNSON (1.78Mn), VANGUARD GROUP INC (1.63Mn), BlackRock, Inc. (1.57Mn).